Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 11, 1999, Pages 1625-1630

  Muller, George W ^a   Chen, Roger ^a   Huang, Shaei Yun ^a   Corral, Laura G ^a   Wong, Lu Min ^a   Patterson, Rebecca T ^a   Chen, Yuxi ^b   Kaplan, Gilla ^b   Stirling, David I ^a  

^a CELGENE CORPORATION   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,6 DIOXO 3 PIPERIDINYL)PHTHALIMIDINE; ALPHA METHYLTHALIDOMIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; MONONUCLEAR CELL; SEDATION; STRUCTURE ACTIVITY RELATION; TERATOGENICITY;

BLOOD; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; STRUCTURE-ACTIVITY RELATIONSHIP; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 0033532557     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00250-4     Document Type: Article

References (24)

1. Stirling, D. I. Pharmaceutical News 1996, 3, 17.
2. Sheskin, J. Clinical Pharmacol. Ther. 1965, 6, 303.
3. (a) Gutierrez-Rodriguez, O. Arth. And Rheum. 1984, 27, 1118. (b) Peterson, D. L.; Georghiou, P. R.; Allworth, A. M; Kemp, R. J. Infection. Clin. Infect. Dis. 1995, 20, 250. (c) Schuler, U.; Ehninger, G. Drug Safety, 1995, 12, 364. (d) Vogelsang, G. B.; Hess, A. D.; Gordon, G.; Brundrette, R.; Santos, G. W. Transplantation Proc. 1987, XIX, 2658. (e) Klausner, J.; Makonkawkeyoon, S.; Akarasewi, P.; Nakata, K.; Kasinrerk, W.; Corral, L.; Dewar, R.; Lane, C.; Freedman, V.; Kaplan, G. J. Acq. Immun. Def. Synd. 1996, 11, 247. (f) Stirling, D.; Sherman, M.; Strauss, S. J. Amer. Pharm. Assoc. 1997, NS37(3).
4. (a) Gutierrez-Rodriguez, O. Arth. And Rheum. 1984, 27, 1118. (b) Peterson, D. L.; Georghiou, P. R.; Allworth, A. M; Kemp, R. J. Infection. Clin. Infect. Dis. 1995, 20, 250. (c) Schuler, U.; Ehninger, G. Drug Safety, 1995, 12, 364. (d) Vogelsang, G. B.; Hess, A. D.; Gordon, G.; Brundrette, R.; Santos, G. W. Transplantation Proc. 1987, XIX, 2658. (e) Klausner, J.; Makonkawkeyoon, S.; Akarasewi, P.; Nakata, K.; Kasinrerk, W.; Corral, L.; Dewar, R.; Lane, C.; Freedman, V.; Kaplan, G. J. Acq. Immun. Def. Synd. 1996, 11, 247. (f) Stirling, D.; Sherman, M.; Strauss, S. J. Amer. Pharm. Assoc. 1997, NS37(3).
5. (a) Gutierrez-Rodriguez, O. Arth. And Rheum. 1984, 27, 1118. (b) Peterson, D. L.; Georghiou, P. R.; Allworth, A. M; Kemp, R. J. Infection. Clin. Infect. Dis. 1995, 20, 250. (c) Schuler, U.; Ehninger, G. Drug Safety, 1995, 12, 364. (d) Vogelsang, G. B.; Hess, A. D.; Gordon, G.; Brundrette, R.; Santos, G. W. Transplantation Proc. 1987, XIX, 2658. (e) Klausner, J.; Makonkawkeyoon, S.; Akarasewi, P.; Nakata, K.; Kasinrerk, W.; Corral, L.; Dewar, R.; Lane, C.; Freedman, V.; Kaplan, G. J. Acq. Immun. Def. Synd. 1996, 11, 247. (f) Stirling, D.; Sherman, M.; Strauss, S. J. Amer. Pharm. Assoc. 1997, NS37(3).
6. (a) Gutierrez-Rodriguez, O. Arth. And Rheum. 1984, 27, 1118. (b) Peterson, D. L.; Georghiou, P. R.; Allworth, A. M; Kemp, R. J. Infection. Clin. Infect. Dis. 1995, 20, 250. (c) Schuler, U.; Ehninger, G. Drug Safety, 1995, 12, 364. (d) Vogelsang, G. B.; Hess, A. D.; Gordon, G.; Brundrette, R.; Santos, G. W. Transplantation Proc. 1987, XIX, 2658. (e) Klausner, J.; Makonkawkeyoon, S.; Akarasewi, P.; Nakata, K.; Kasinrerk, W.; Corral, L.; Dewar, R.; Lane, C.; Freedman, V.; Kaplan, G. J. Acq. Immun. Def. Synd. 1996, 11, 247. (f) Stirling, D.; Sherman, M.; Strauss, S. J. Amer. Pharm. Assoc. 1997, NS37(3).
7. (a) Gutierrez-Rodriguez, O. Arth. And Rheum. 1984, 27, 1118. (b) Peterson, D. L.; Georghiou, P. R.; Allworth, A. M; Kemp, R. J. Infection. Clin. Infect. Dis. 1995, 20, 250. (c) Schuler, U.; Ehninger, G. Drug Safety, 1995, 12, 364. (d) Vogelsang, G. B.; Hess, A. D.; Gordon, G.; Brundrette, R.; Santos, G. W. Transplantation Proc. 1987, XIX, 2658. (e) Klausner, J.; Makonkawkeyoon, S.; Akarasewi, P.; Nakata, K.; Kasinrerk, W.; Corral, L.; Dewar, R.; Lane, C.; Freedman, V.; Kaplan, G. J. Acq. Immun. Def. Synd. 1996, 11, 247. (f) Stirling, D.; Sherman, M.; Strauss, S. J. Amer. Pharm. Assoc. 1997, NS37(3).
8. (a) Gutierrez-Rodriguez, O. Arth. And Rheum. 1984, 27, 1118. (b) Peterson, D. L.; Georghiou, P. R.; Allworth, A. M; Kemp, R. J. Infection. Clin. Infect. Dis. 1995, 20, 250. (c) Schuler, U.; Ehninger, G. Drug Safety, 1995, 12, 364. (d) Vogelsang, G. B.; Hess, A. D.; Gordon, G.; Brundrette, R.; Santos, G. W. Transplantation Proc. 1987, XIX, 2658. (e) Klausner, J.; Makonkawkeyoon, S.; Akarasewi, P.; Nakata, K.; Kasinrerk, W.; Corral, L.; Dewar, R.; Lane, C.; Freedman, V.; Kaplan, G. J. Acq. Immun. Def. Synd. 1996, 11, 247. (f) Stirling, D.; Sherman, M.; Strauss, S. J. Amer. Pharm. Assoc. 1997, NS37(3).
9. Sampaio, E. P.; Sarno, E. N.; Galilly, R.; Cohn, Z. A.; Kaplan, G. J. Exp. Med. 1991, 173, 699.
10. Eigler, A.; Sinha, B.; Hartmann, G.; Endres, S. Immunology Today 1997, 18, 487.
11. (a) van Dullemen, H; van Deventer, S; Hommes, D; Bijl, L; Jansen, J; Tytgat, G; Woody, J. Gastroenterology 1995, 109, 129. (b) Elliott, M.; Feldmann, M.; Maini, R. Int. J. Immunopharmac. 1995, 17, 141.
12. (a) van Dullemen, H; van Deventer, S; Hommes, D; Bijl, L; Jansen, J; Tytgat, G; Woody, J. Gastroenterology 1995, 109, 129. (b) Elliott, M.; Feldmann, M.; Maini, R. Int. J. Immunopharmac. 1995, 17, 141.
13. Muller, G. W.; Corral, L. G; Shire, M. G.; Wang, H.; Moreira, A.; Kaplan, G.; Stirling, D. I. J. Med. Chem. 1996, 39, 3238.
14. Muller, G.W.; Shire, M. G.; Wong, L. M.; Corral, L. G.; Patterson, R. T.; Chen, Y.; Stirling, D. I. Bioorg. Med. Chem. Lett. 1998, 8, 2669.
15. Torphy, T. J. Am. J. Resp. Crit. Care 1998, 757, 351.
16. th American Chemical Society, Chicago, IL, Fall 1993; Med. Chem., paper 216.
17. Heger, W.; Schmahl, H.; Klug, S.; Felies, A.; Nau, H.; Merker, H.; Neubert, D. Teratogenesis, Carcinogenesis, and Mutagenesis 1994, 14, 115.
18. Muller, G. W.; Stirling, D. I.; Chen, R. S. C. United States Patent No. 5,635,517, 1997. Chem. Abstr. 1997, 127, 86110.
19. Chiral HPLC analyses were carried out at 240 nM using a Daicel chiralpak AD column (0.46 × 25 cm) eluting with 30/70 hexane/IPA at 0.75mL/min.
20. Siedlecka, R.; Skarzewski, J. Pol. Synth. Commun. 1997, 27, 2081.
21. Casini, G.; Ferappi, M. Farmaco, Ed. Sci. 1964, 563.
22. Wnedt, S.; Finkam, M.; Wniter, W.; Ossig, J.; Raabe, G; Zwingenberger, K. Chirality 1996, 8, 390.
23. Miyachi, H.; Koiso, Y.; Shirali, R; Niwayama, S.; Liu, J. O.; Hashimoto, Y. Chem. Pharm. Bull. 1998, 46, 1165.
24. Corral, L. G.; Haslett, P. A.; Muller, G. W.; Chen, R.; Wong, M. L.; Ocampo, C.; Stirling D. I.; Kaplan, G. J. Immun. accepted.